These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 583466)
1. Absorbed dose to ovaries or uterus during a 131I-therapeutic of cancer or hyperthyroidism: comparison between in vivo measurements by TLD and calculations. Briere J; Philippon B Int J Appl Radiat Isot; 1979 Oct; 30(10):643-6. PubMed ID: 583466 [No Abstract] [Full Text] [Related]
2. Absorbed dose to ovaries and uterus during 131I-treatment of hyperthyroidism: comparison between in vivo TLD measurements and calculations. Philippon B; Briere J Health Phys; 1979 Jun; 36(6):727-9. PubMed ID: 582449 [No Abstract] [Full Text] [Related]
3. Normalized organ doses for various diagnostic radiologic procedures. Gray JE; Ragozzino MW; Van Lysel MS; Burke TM AJR Am J Roentgenol; 1981 Sep; 137(3):463-70. PubMed ID: 6974456 [TBL] [Abstract][Full Text] [Related]
4. Estimated Dose to Family Members of Patients Treated with Radioiodine. Kochovska MZ; Jokic VS; Majstorov V; Dugonjic S Radiat Prot Dosimetry; 2017 Apr; 174(2):250-254. PubMed ID: 27247441 [TBL] [Abstract][Full Text] [Related]
5. [The efficacy of lead shielding in patient dosage reduction in computed tomography]. Hidajat N; Schröder RJ; Vogl T; Schedel H; Felix R Rofo; 1996 Nov; 165(5):462-5. PubMed ID: 8998318 [TBL] [Abstract][Full Text] [Related]
6. Surface dose measurement in patients and physicians and effective dose estimation in patients during uterine artery embolisation. Nishizawa K; Masuda Y; Morinaga K; Suzuki S; Kikuyama S; Yoshida T; Ohno M; Akahane K; Iwai K Radiat Prot Dosimetry; 2008; 128(3):343-50. PubMed ID: 18337296 [TBL] [Abstract][Full Text] [Related]
7. Radiation dose to family members of hyperthyroidism and thyroid cancer patients treated with 131I. Pant GS; Sharma SK; Bal CS; Kumar R; Rath GK Radiat Prot Dosimetry; 2006; 118(1):22-7. PubMed ID: 16105892 [TBL] [Abstract][Full Text] [Related]
8. In vivo dose verification of IMRT treated head and neck cancer patients. Engström PE; Haraldsson P; Landberg T; Sand Hansen H; Aage Engelholm S; Nyström H Acta Oncol; 2005; 44(6):572-8. PubMed ID: 16165916 [TBL] [Abstract][Full Text] [Related]
10. Radiation dose to the testes after 131I therapy for ablation of postsurgical thyroid remnants in patients with differentiated thyroid cancer. Ceccarelli C; Battisti P; Gasperi M; Fantuzzi E; Pacini F; Gualdrini G; Pierantoni MC; Luciani A; Djokich D; Pinchera A J Nucl Med; 1999 Oct; 40(10):1716-21. PubMed ID: 10520714 [TBL] [Abstract][Full Text] [Related]
11. [Organ dose and conversion coefficients applied to gonads and uterus in enteroclysis with double contrast technique]. Weiner GM; Köhler B; Golder W Rofo; 2003 Nov; 175(11):1551-5. PubMed ID: 14610708 [TBL] [Abstract][Full Text] [Related]
12. Measurement of the Dose to the Family Members Taking Care of Thyroid Cancer Patients Undergoing I-131 Therapy in Nuclear Medicine Using TLD-100. Zehtabian M; Dehghan N; Danaei Ghazanfarkhani M; Haghighatafshar M; Sina S Radiat Prot Dosimetry; 2017 May; 174(4):541-544. PubMed ID: 27555655 [TBL] [Abstract][Full Text] [Related]
13. Is standard 555 MBq 131I-therapy of hyperthyroidism ablative? Bertelsen J; Herskind AM; Sprogøe Jakobsen U; Hegedüs L Thyroidology; 1992 Dec; 4(3):103-6. PubMed ID: 1285034 [TBL] [Abstract][Full Text] [Related]
15. A study of the possibility of curing Graves' disease based on the desired reduction of thyroid mass (volume) as a consequence of 131I therapy: a speculative paper. Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M Nucl Med Commun; 2006 May; 27(5):439-46. PubMed ID: 16609355 [TBL] [Abstract][Full Text] [Related]
17. A predictive mathematical model for the calculation of the final mass of Graves' disease thyroids treated with 131I. Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M Phys Med Biol; 2005 May; 50(9):2181-91. PubMed ID: 15843745 [TBL] [Abstract][Full Text] [Related]
18. Radionuclide hysterosalpingography with technetium-99m-pertechnetate: application and radiation dose to the ovaries. Yang KT; Chiang JH; Chen BS; Liang CH; Lee SF; Liao SC J Nucl Med; 1992 Feb; 33(2):282-6. PubMed ID: 1310106 [TBL] [Abstract][Full Text] [Related]
19. Does thyroid stunning exist? A model with benign thyroid disease. Sabri O; Zimny M; Schreckenberger M; Meyer-Oelmann A; Reinartz P; Buell U Eur J Nucl Med; 2000 Nov; 27(11):1591-7. PubMed ID: 11105814 [TBL] [Abstract][Full Text] [Related]
20. Therapeutic administration of 131I for differentiated thyroid cancer: radiation dose to ovaries and outcome of pregnancies. Garsi JP; Schlumberger M; Rubino C; Ricard M; Labbé M; Ceccarelli C; Schvartz C; Henri-Amar M; Bardet S; de Vathaire F J Nucl Med; 2008 May; 49(5):845-52. PubMed ID: 18413399 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]